National Expenditures on Anticancer and Immunomodulating Agents During 2013–2022 in Korea DOI Creative Commons
Jieun Yun, Youngs Chang,

Masayasu Jo

et al.

Journal of Korean Medical Science, Journal Year: 2024, Volume and Issue: 40(5)

Published: Nov. 9, 2024

This study investigated trends in national expenditures on anticancer and immunomodulating agents from 2013 to 2022. Information was obtained the National Health Insurance claims data spanning a period of 10 years, The subjects this are patients diagnosed with cancer who used between January 1, 2013, December 31, Trends were examined across various categories, including sex, age groups, routes healthcare use, types institutions. We calculated compound annual growth rate both number by year. In pharmaceutical amounted USD 11,984 million, representing 25.5% total expenditures, which 46,984 million. Within expenditure, medications constituted 584 or 4.9%. By 2022, had risen 22,093 accounting for 22.8% 96,904 Of amount, 1,566 million allocated drugs, represented 7.1% expenditures. Between experienced significant increase 106.2%, reaching 49,920 Concurrently, rose 91.1% 10,919 while drugs surged 168.2% 982 category highest ATC L01FF, includes programmed cell death protein 1/death ligand 1 inhibitors such as nivolumab, totaling 266.2 followed L01FD at 198.8 L01EA 140.4 Since 2018, however, spending immune checkpoint blockers targeting proteins ligands has continued rise currently ranks first. using associated drug have As share grows, so too do overall escalating financial burden highlights necessity policymakers thoroughly understand appropriate cost-effective usage it directly influences affordability accessibility services.

Language: Английский

Incidence of Clostridioides difficile Infections in Republic of Korea: A Prospective Study With Active Surveillance vs. National Data From Health Insurance Review & Assessment Service DOI Creative Commons
Jieun Kim, Rangmi Myung, Bongyoung Kim

et al.

Journal of Korean Medical Science, Journal Year: 2024, Volume and Issue: 39(12)

Published: Jan. 1, 2024

Since the emergence of hypervirulent strains

Language: Английский

Citations

7
Quantitative and qualitative evaluation of antimicrobial usage: the first step for antimicrobial stewardship DOI Creative Commons
Song Mi Moon, Bongyoung Kim, Hong Bin Kim

et al.

The Korean Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 39(3), P. 383 - 398

Published: April 30, 2024

The identification of antimicrobial use patterns is essential for determining key targets stewardship interventions and evaluating the effectiveness thereof. Accurately identifying requires quantitative evaluation, which focuses on measuring quantity frequency use, qualitative assesses appropriateness, effectiveness, potential side effects prescriptions. This paper summarizes methods used to evaluate antimicrobials, drawing insights from overseas domestic cases.

Language: Английский

Citations

5
Significance of The Regular Publication of Statistics on National Health Indicators in Academic Journals and The Prospects of Korea National Antimicrobial Use Analysis System (KONAS) DOI Creative Commons
Bongyoung Kim, Yong Chan Kim, Hyung-Sook Kim

et al.

Infection and Chemotherapy, Journal Year: 2023, Volume and Issue: 55(2), P. 306 - 306

Published: Jan. 1, 2023

Language: Английский

Citations

8
Principles and practices of antimicrobial stewardship programs in Korea DOI Creative Commons
Ki Tae Kwon, Shin‐Woo Kim

The Korean Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 39(3), P. 373 - 382

Published: April 23, 2024

This review addresses the escalating challenge posed by antibiotic resistance, highlighting its profound impact on global public health, including increased mortality rates and healthcare expenditures. The focuses need to adopt One Health approach effectively manage usage across human, animal, environmental domains. Antimicrobial stewardship programs (ASPs) are considered as comprehensive strategies that encompass both core supplementary initiatives aimed at enhancing prudent use. 2021 “Guidelines Implementing ASP in Korea” introduced such strategies, with a strong emphasis fostering multidisciplinary collaborative efforts. Furthermore, “Core Elements for ASPs Korean General Hospitals,” established 2022, provide structured framework ASPs, delineating leadership responsibilities, composition of interdisciplinary teams, range interventions, continuous monitoring reporting mechanisms. In addition, this examines patient-centric campaigns “Speak Up, Get Smart” emphasizes pivotal role international cooperation addressing multifaceted challenges associated resistance.

Language: Английский

Citations

0
Implementing antimicrobial stewardship: lessons and perspectives from a university-affiliated tertiary hospital in Korea DOI Creative Commons
Soo Jin Lee, Raeseok Lee, Sung‐Yeon Cho

et al.

The Korean Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 39(3), P. 399 - 412

Published: April 30, 2024

Antimicrobial stewardship programs (ASPs) can lower antibiotic use, decrease medical expenses, prevent the emergence of resistant bacteria, and enhance treatment for infectious diseases. This study summarizes stepwise implementation effects ASPs in a single university-affiliated tertiary care hospital Korea; it also presents future directions challenges resource-limited settings. At hospital, core elements ASP such as leadership commitment, accountability, operating system were established 2000, then strengthened by formation Stewardship (AMS) Team 2018. The actions entail key components including computerized restrictive prescription system, prospective audit, post-prescription review through quantitative qualitative intervention, pharmacy-based interventions to optimize usage. AMS regularly tracked interventions, resistance patterns pathogens hospital. reporting was enhanced standardized participation Korea National Use Analysis System, educational efforts are ongoing. Stepwise have led substantial reduction overall consumption antibiotics, particularly regarding injectables, optimization use. Our experience highlights importance leadership, institution-specific Team.

Language: Английский

Citations

0
National Expenditures on Anticancer and Immunomodulating Agents During 2013–2022 in Korea DOI Creative Commons
Jieun Yun, Youngs Chang,

Masayasu Jo

et al.

Journal of Korean Medical Science, Journal Year: 2024, Volume and Issue: 40(5)

Published: Nov. 9, 2024

This study investigated trends in national expenditures on anticancer and immunomodulating agents from 2013 to 2022. Information was obtained the National Health Insurance claims data spanning a period of 10 years, The subjects this are patients diagnosed with cancer who used between January 1, 2013, December 31, Trends were examined across various categories, including sex, age groups, routes healthcare use, types institutions. We calculated compound annual growth rate both number by year. In pharmaceutical amounted USD 11,984 million, representing 25.5% total expenditures, which 46,984 million. Within expenditure, medications constituted 584 or 4.9%. By 2022, had risen 22,093 accounting for 22.8% 96,904 Of amount, 1,566 million allocated drugs, represented 7.1% expenditures. Between experienced significant increase 106.2%, reaching 49,920 Concurrently, rose 91.1% 10,919 while drugs surged 168.2% 982 category highest ATC L01FF, includes programmed cell death protein 1/death ligand 1 inhibitors such as nivolumab, totaling 266.2 followed L01FD at 198.8 L01EA 140.4 Since 2018, however, spending immune checkpoint blockers targeting proteins ligands has continued rise currently ranks first. using associated drug have As share grows, so too do overall escalating financial burden highlights necessity policymakers thoroughly understand appropriate cost-effective usage it directly influences affordability accessibility services.

Language: Английский

Citations

0